Data from the National Cancer Database, which is heavily dependent on institutional reporting, could be misleading about the burden of sarcomas in the United States. READ MORE
Health-related quality of life and its impact on disease progression should be a consideration when selecting treatment for sarcoma.
Data from the National Cancer Database, which is heavily dependent on institutional reporting, could be misleading about the burden of sarcomas in the United States.
A recent analysis showed that aftercare strategies for soft-tissue sarcoma are misguided and are in need of time- and risk-adapted methods.
Long-term therapy with a recently approved drug is well tolerated in patients with soft-tissue sarcoma.
A recent analysis examined whether changes to the latest American Joint Committee on Cancer cancer staging manual on retroperitoneal sarcoma have improved staging system performance.
Research in Review
The best potential strategy involving tyrosine kinase inhibitors for the treatment of gastrointestinal stromal tumors has been identified.
Kaposi Sarcoma (KS) skin lesions are more likely to respond to local external beam radiotherapy than repeat radiotherapy.
Tivozanib was well-tolerated and showed promising antitumor activity in patients with soft tissue sarcoma overexpressing vascular endothelial growth factors, supporting efforts for further research.
Neoadjuvant chemotherapy with epirubicin plus ifosfamide improves outcomes in patients with soft tissue sarcoma who are at high-risk of recurrence.